MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer
Dr. Frédéric Sedel to Transition to CSO
PARIS, July 26, 2018 (GLOBE NEWSWIRE) -- MedDay, a pioneering pharmaceutical company focused on the treatment of nervous system disorders, today announces the appointment of Christian Chavy MBA as Chief Executive Officer, effective 27th August 2018.
Mr. Chavy will succeed Dr. Frédéric Sedel, CEO and Co-Founder of MedDay, who will remain in his existing role until August 27th. Dr. Sedel will then transition to Chief Scientific Officer and continue to serve on the board of directors.
Commenting on the appointment, Catherine Moukheibir, Chairman of the board, said, "We are thrilled to have Christian take on the role of CEO at this critical time for MedDay as we execute on our confirmatory Phase III clinical trial of MD1003 in progressive MS and make preparations to become a commercial stage company."
"On behalf of the Board of Directors, I would also like to thank Dr. Frédéric Sedel, our co-founder, who has been instrumental in building MedDay into the company that it is today and has laid the groundwork for a company that ultimately should bring innovative treatments for patients," continued Mrs. Moukheibir. "Under his leadership, MedDay has advanced our lead candidate MD1003 into late stage clinical development, including completion of a successful Phase III trial in progressive MS, and is building a pipeline of promising candidates to treat CNS diseases. The appointment of Christian Chavy represents a continuation of this strategy. We look forward, also, to further contributions from Frédéric Sedel in his new role as Chief Scientific Officer."
Mr. Christian Chavy commented, "I am honored to be appointed CEO of MedDay. MD1003, which has a novel mechanism of action and which has already demonstrated strong clinical activity, is positioned to transform the treatment paradigm for progressive multiple sclerosis. We look forward to completing the Phase III trial and see a clear path to approval in the major markets, including U.S. and EU. MedDay is also dedicated to finding effective treatments for severe diseases of the nervous system through our pioneering work of targeting brain metabolism."
Dr. Frédéric Sedel commented, "I am convinced that Christian Chavy has the right skill set and vision to bring MedDay to the next stage. I am very excited with my new role as company CSO which I believe is the area where I can create the most value."
Mr. Chavy is a highly accomplished pharmaceutical executive with experience in Europe and North America. Most recently, he was the CEO of Stallergenes (2014-2016) and Partner at Ares Life Sciences (2010-2014). His career highlights include 9 years at Actelion Pharmaceuticals (2000-2009) where he was promoted to President of Global Operations, with responsibility over USA, Europe, Japan and rest of the world. Prior to joining Actelion, he was VP, Head of the reproductive health commercial unit at Serono in Geneva and Chairman of Serono's French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France. Earlier in his career he held roles of increasing responsibility at Bristol-Myers France, SmithKline and French Laboratories, and Merck Sharpe & Dohme.
Mr. Chavy is currently chairman of the board of Ixaltis, a specialty pharmaceutical company developing innovative treatment for genitourinary tract disorders that he founded, and serves on the board of Cerenis. He is a graduate of the Ecole Supérieure des Sciences Economiques et Commerciales (ESSEC) and the Institut de Contrôle de Gestion (ICG).
MedDay is a pioneering pharmaceutical company targeting brain metabolism to treat nervous system disorders. The company was founded in 2011. The lead product, MD1003 is a formulation of high dose Pharmaceutical grade Biotin (hdPB) developed for progressive multiple sclerosis and other demyelinating diseases. The R&D pipeline also includes MD1103 in autism spectrum disorders and MD1105 in Alzheimer's disease.
MedDay explores brain metabolic pathways through its metabolomics research platform, SPECMET, which supports the discovery of additional pipeline assets. SPECMET screens cerebrospinal fluid (CSF) from patients with various Central Nervous System (CNS) disorders to identify the disrupted metabolic pathways. Compounds that are known to affect these metabolic pathways are then identified and further developed. SPECMET was developed in collaboration with the Commissariat à l'Energie Atomique (CEA) and in March 2017, MedDay acquired the health division of Profilomic SA, an innovative company formed out of the CEA in 2010, which significantly strengthened MedDay's research capabilities as the company aims to expand its pipeline.
MedDay is well funded by investors including Sofinnova Partners, InnoBio, Andera Partners and Bpifrance Large Venture. MedDay is headquartered in Paris and has a team in Boston.
For more information, please see: www.medday-pharma.com. Follow us on Twitter: @MedDayPharm.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Meddday Pharmaceuticals via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Elite Capital & Gas broadens financial services and signs a deal with Tabarak Investment Capital Limited17.10.2018 16:30 | Pressemelding
DUBAI, United Arab Emirates, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Today the President of Elite Petro & Gas, Mr. George Matharu and the President of Tabarak Investment Capital Limited (Investment Bank), Dr. Mohamed Ahmadi announced a deal in which the two companies will use their combined resources to execute physical commodity trades, and provide banking and finance facilities for oil and gas transactions. The alliance between the two entities will also allow compliance related activities to be carried out from two major international hubs of London and Dubai. This increases the international presence of both companies. Additionally, Elite Petro & Gas (“EPG”) has recently formed relationships with the owners of a number of high profile European, South American and Chinese projects, which EPG and Tabarak can work on together. Tabarak Investment Capital Limited is a regulated investment bank by Dubai Financial Services Authority and incorporated in the Dubai International Financial Centre.
MASH ANNOUNCES EUR 50M EQUITY ROUND AND LAUNCH OF EUROPE'S FIRST STO17.10.2018 15:14 | Pressemelding
Mash Group, a ten year old digital lender and pay later solution provider, announced a EUR 50M equity round and the launch of a Security Token Offering (STO) Helsinki, 17th October: Mash Group Plc, a Finnish FinTech company specializing in consumer lending and pay later solutions, today announced that pre-registration has begun for a Securitized Token Offering (STO). Mash is partnering with DLA Piper, Trust and Tokeny to offer professional investors the means to participate in the current equity round using both crypto and fiat currency. Deloitte has been selected to provide AML and KYC services. The whitelisting process will begin in October with the round closing in December 2018. The STO is part of Mash’s broader EUR 50 million equity round. Security tokens are not the same as utility tokens, as have been issued in a number of recent initial coin offerings (ICOs). The Mash security tokens are backed by assets and token holders would have voting rights and dividend rights of the comp
Meizu officially launches its Overseas smartphone17.10.2018 15:13 | Pressemelding
Jakarta, Indonesia, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Meizu officially launches its Overseas smartphone, produced in and to be sold in the Indonesian market, the C9, as well as 4 other fantastic products, including the Flagship Meizu 16th, the upgraded M6T, POP true wireless earphones and EP52 Lite. A photo accompanying this announcement is available at https://i.imgur.com/C4LvxTd.png ( Jakarta, Indonesia October 15th, 2018) -- Meizu is releasing 5 exciting products, including 3 smartphone models, its iconic flagship 16th, M6T, C9, POP and EP52 Lite earphones). Meizu’s product launch event is set for the 15th October 2018 at the Pullman hotel in Jakarta Indonesia, with a great line-up of speakers, including Meizu’s Co-Founder and Overseas President Mr Guo, and overseas Head of Marketing and packed with over 150 of Indonesia’s top media, bloggers and fans, it’s set to be a fantastic event all round. Meizu is releasing five great products and introducing 2 years’ warranty on their smartp
eVestment Launches Market Lens to Arm Asset Managers with Next Level Insights to Win More Institutional Investment Mandates17.10.2018 15:00 | Pressemelding
ATLANTA, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Institutional asset managers looking for the next level of insights in their pursuit of institutional investment mandates can now turn to Market Lens from eVestment, a global leader in institutional investor data and analytics. Market Lens offers a robust feature set including a comprehensive mandate database; investor, consultant and manager profiles; and more than 35,000 documents, audio recordings and videos. These assets include manager presentations, consultant recommendations and research. The new solution also features customized email alerts, saved searches and export capabilities for easy integration into client workflows. The underlying public fund documents allow Market Lens to feature unique investment insights, including product ratings, target asset allocation, actual negotiated fees paid and, leveraging eVestment relationships with institutional investment consultants, undisclosed consultant search data. “In their efforts to win
Kofax Intelligent Automation Deployment at Davies Turner Wins Ventana Award for Overall Digital Leadership17.10.2018 12:00 | Pressemelding
Project Recognized for Driving Real-Time Insight into Shipments and Inventory to Transform the Customer Experience; Other Kofax Customers also Receive Accolades IRVINE, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Kofax ® , a leading supplier of intelligent automation (IA) software to digitally transform end-to-end business processes, today announced its customer Davies Turner, one of the UK’s leading multimodal freight forwarding and logistics companies, won the 2018 Overall Digital Leadership Award from Ventana Research for its successful implementation of Kofax Intelligent Automation. Kofax customers Pinnacol Assurance and PITT-OHIO were also recognized. “Davies Turner’s commitment to automation was ambitious but the perfect match for Kofax Intelligent Automation,” said Reynolds C. Bish, Chief Executive Officer of Kofax. “This award is a great illustration of how Kofax enables increased productivity to help organizations remain on track for profitable growth and significant competitive
2018 European Cost Insight Product Cost Management Conference17.10.2018 10:00 | Pressemelding
Companies from Across Europe to Gather and Discuss How PCM Strategies & Technologies Improve Profitability & Accelerate Design to Delivery Time CONCORD, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- aPriori, the leading provider of enterprise product cost management (PCM) software solutions, announces today that it will host the European Cost Insight Product Cost Management Conference on November 26-28, 2018. This year’s event is being held at Hilton Amsterdam Airport Schiphol in Amsterdam, The Netherlands. This event is open to both aPriori customers and representatives from any manufacturers that are interested in learning more about product cost management technology and best practices. Visit the Cost Insight 2018 Event Website for complete information and register for this year’s program. Why Should You Attend Cost Insight 2018? As pressure increases to deliver innovative and customized products to market faster, manufacturers are struggling to maintain product profits and accelerate de
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom